WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 15-Jul-2014 (Data received as of 8-Jul-2014)
Next overall update Fall 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 102'6101 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 65'4611 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 5'043  4'994  4'944  4'891  4'836  4'492  4'240  4'083 
Births 63  62  62  61  61  58  58  50 
Surviving infants 62  62  61  61  61  58  58  50 
Pop. less than 5 years 322  319  314  306  301  302  280  261 
Pop. less than 15 years 940  935  928  920  917  899  803  906 
Female 15-49 years 1'163  1'154  1'146  1'137  1'126  1'067  1'055  925 

Number of reported case

(Click for retrospective incidence data for Norway)
Diphtheria
Japanese encephalitis
Measles 39  95  1'322 
Mumps 35  30  16  12  12 
Pertussis 2'608  4'231  3'695  3'565  5'546  3'417  208  2'003 
Polio*
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Norway)
Vaccine year result method % card seen                                                
BCG          88  91 
DTP1          99  100  99  99  99 
DTP3          94  95  94  93  94  90  86 
HepB_BD         
HepB3         
Hib3          95  95  95  94  95  93 
JapEnc         
MCV          93  94  93  93  93  88  87 
MCV2          91  91  94  97  96  90 
PCV1          99  99  99  98 
PCV3          93  93  92  91  91 
Pol3          94  95  94  93  94  91  84 
Rota1         
Rota_last         
Rubella1          93  94  93  93  92 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Norway)
DTP1 99  99  99  99  99  99  95 
DTP3 94  95  94  93  94  90  86 
HepB3
HepB_BD
Hib3 95  95  95  94  95  93 
MCV 93  94  93  93  93  88  87 
MCV2 91  91  94  97  96  90 
PCV3 93  93  92  91  91 
Pol3 94  95  94  93  94  91  84 
Rota_last

Number of districts in the country 19  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG Yes Defined risk
DTaPHibIPV 3, 5, 12 months; Yes
DTaPIPV 7 years; Yes
HepB birth; 1, 6 months; adults; Yes defined risk groups
HPV 12 years (x3); Yes girls
Influenza Defined risk
IPV 15 years; Yes
MMR 15 months; 11 years; Yes
Pneumo_conj 3, 5, 12 months; Yes
TdIPV 15 years;

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No       

System performance

Total Nº districts in country number 19  19  19  19  19  19  19 
Nº districts with DTP3 coverage >=80% number 19  19  19  19  18  19 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  95  100  11 
Nº districts with measles (MCV1) coverage >=95% number  
% of districts with MCV1 coverage >=95% From 0 to 100% 11  42  37  16   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  74  63  60 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.